Allergan Acquires Rights To CONSTELLA In More Than 40 Countries - Quick Facts

(RTTNews) - Allergan plc (AGN) and Ironwood Pharmaceuticals, Inc. (IRWD) announced that Allergan has acquired rights to CONSTELLA (linaclotide) in the European Union, Switzerland, Turkey and the Commonwealth of Independent States from Almirall, S.A. Allergan acquired an exclusive license for CONSTELLA in these countries. Allergan plc has also reacquired rights to LINZESS (linaclotide) in Mexico from Almirall.

CONSTELLA is currently approved by the European Commission for the symptomatic treatment of moderate-to-severe irritable bowel syndrome with constipation in adults.

Linaclotide was approved in 2012 by the European Commission and, until assumed by Allergan under the announced transaction, was marketed in a number of European countries under the brand name CONSTELLA through a license agreement between Ironwood and Almirall.